Pacific Rim Electrophysiology Research Institute
33 Soi Sukhumvit 3, Khwaeng Khlong Toei Nuea, Khet Watthana
,
Phone:

Dr. Koonlawee Nademanee Curriculum Vitae

Education

High School

Triam-Udomsuksa School, Bangkok, Thailand

University

Chulalongkorn University: BSc, 1971
Bangkok, Thailand

Medical School

Chulalongkorn University: MD, 1973
Medical School: Bangkok, Thailand
Second Class Honor

Internship

Straight Medical Intern: July 1975-June 1976
Tulane University, Touro Infirmary,
New Orleans, Louisiana

Residencies

Medical Resident: July 1976-June 1978
Tulane University, Touro Infirmary,
New Orleans, Louisiana

Fellowship

Cardiology Fellow: July 1978-June 1980
West Los Angeles VA Medical Center,
Department of Medicine, Los Angeles, California

Honors and Awards

2005
Honorary Doctorate in Medicine: Mahidol University, Bangkok, Thailand

March 19,1999
Outstanding Service Merit Award: 50th Anniversary of Bhumibol Adulyadej Hospital, Royal Thai Air Force-Golden Jubilee Celebration, Bangkok, Thailand

1995
Special Recognition for Excellence in Clinical Consultation of LAAM’s Effects on the Human Electrocardiogram: Medications Development Division. National Institute on Drug Abuse, 1995

1994
Honourary Consultation in Cardiology at Bhumibol Adulyadej Hospital, Bangkok, Thailand

1994
Outstanding Service Merit Award from the Division of Cardiology at University of Colorado

1993
Denver Health and Hospitals Senior Faculty Scholarly Achievement Award

1993
Visiting Professor of Cardiology at Her Majesty’s Cardiac Centre, Siriraj Hospital, Bangkok, Thailand, for the academic year

Second Class Honors for excellence in Cardiology, Touro Infirmary, Tulane University

Patents

Mapping of Complex Fractionated Atrial Electrograms (CFAE)
US Patent and Trademark Office, Department of Commerce
Patient Number 11/620,370

Licensure

California, July 1978: No. A 032891

Colorado, April 1990: No. 30166

Hawaii, August 1997: No. MD-9979

Board Certification

Diplomate in American Board of Internal Medicine, September 1978

Diplomate in American Board of Cardiovascular Disease, November 1981

Diplomate in American Board of Clinical Cardiac Electrophysiology, June 1994

Professional Background

Academic Appointments

2000-2004
Clinical Professor of Medicine
University of Southern California

1995-2000
Professor of Medicine (Tenure)
University of Southern California

1990-1995
Professor of Medicine (Tenure)
University of Colorado

1986-1990
Associate Professor of Medicine (Tenure)
University of California, Los Angeles
School of Medicine

1980-1986
Assistant Professor of Medicine
University of California, Los Angeles
School of Medicine

Specific Teaching Responsibilities

January 1995-2000
Electrophysiology Tracing Rounds, Division of Cardiology, Electrophysiology Service, USC School of Medicine

January 1995-2000
Cardiology Conference at Los Angeles County + USC Medical Center for cardiology fellows, medical staff, and medical students

July 1990-Nov 1994
Cardiology Conference at Denver General Hospital for cardiology fellows, medical staff, and medical students

July 1990-Nov 1994
Lecturer in cardiac arrhythmias and electrophysiology for Department of Medicine, Emergency Department and Rocky Mountain Poison Center

1992
Introduction course in pathophysiology of cardiovascular diseases, University of Colorado

1987-1990
“How to Manage Cardiac Arrhythmias” lecture every six weeks to resident staff at West Los Angeles VA Medical Center

1986-1990
EKG lecture for staff and fellows bimonthly at West Los Angeles VA Medical Center

1987-1990
Course in EKG to third-year clerkship medical students, UCLA

1987-1990
Conducting Electrophysiology Conference every Friday at West Los Angeles VA Medical Center

Specific Administrative Responsibilities

July 2003-Present Director, Heart Rhythm Institute, Centinela Hospital Medical Center

July 2000-Present Director, Pacific Rim Electrophysiology Research Institute

July 2000-2003 Director of Electrophysiology at Tommy Lasorda Heart Institute, Centinela Hospital Medical Center

Jan 1995-June 2000 Director of Electrophysiology and Pacing USC School of Medicine

July 1990-Dec 1994 Chief of Cardiology Denver General Hospital

July 1984-June 1990 Director of Clinical Electrophysiology West Los Angeles VA Medical Center

Oct 1981-June 1984 Acting Chief, Coronary Care Unit West Los Angeles VA Medical Center

July 1980-Present Staff Physician in Cardiology West Los Angeles VA Medical Center

Other Professional Activities

Editorial Boards

November 2007 Journal of Atrial Fibrillation

October 2007-Present The Journal of Cardiology Official Journal for the Japanese College of Cardiology

October 1994-October 2007 Journal of Cardiovascular Pharmacology and Therapeutics

July 1991-1993 Journal of the American College of Cardiology

July 1991-1994 Circulation

Frequent reviewer for: American Journal of Cardiology; American Journal of Medicine; Annals of Internal Medicine; American Heart Journal; Journal of Cardiovascular Electrophysiology; Journal of the American Medical Association; and Pacing and Clinical Electrophysiology, Heart Rhythm, Journal of the American College of Cardiology, and Circulation

Committee Memberships

2006 Council Member of the Heart Rhythm Society Task Force to develop an expert consensus statement on catheter ablation of atrial fibrillation

2000-2002 Council Member of the American Heart Association National Committee on Electrocardiography and Arrhythmia on Clinical Cardiology: Silver Member

1997-2000 Executive Peer Review Committee for USC University Hospital

1993-1994 Executive Committee for the AVID study

1990-1994 Executive Committee for Department of Cardiology, University of Colorado

1990-1994 Fellowship Committee, Department of Cardiology, University of Colorado

1990-1994 Executive Committee for Academic Senate, University of Colorado

1992-1994 Research Committee for American Heart Association of Colorado

1991-1994 Critical Care Committee, Denver General Hospital

1989-1994 Member, VA Department of Medicine ad hoc Committee on Department Computing

1988-1990 Institutional Review Board, West Los Angeles VA Medical Center

1989-1990 Western Region AICD Advisory Group, Veterans Administration

1986-1990 Member, Academic Senate, UCLA

Society Memberships

Local

  • Greater Los Angeles American Heart Association
  • Chairman, Greater Los Angeles American Heart Association 65th Annual Fall Symposium
  • Planning Committee, Greater Los Angeles American Heart Association 67th Annual Fall Symposium

National

  • Membership in the Western Society for Clinical Investigation
  • Fellow of the American College of Cardiology
  • Fellowship in the Council on Circulation of the American Heart Association
  • Membership in the Heart Rhythm Society
  • Cardiac Electrophysiology Society (Heart Rhythm Society)

Consultantships

Honorary Consultant in Cardiology for Thai Air Force Medical Center, Thailand

Consultant for Her Majesty’s Cardiac Center Mahidol University

Consultant for NIDA “LAMM Development”

National and International Invited Lectures and Visiting Professorships

1996

“SUDS: Sudden Unexpected Death Syndrome in Southeast Asia: Research in Progress” Cardiology Grand Rounds at University of Southern California. Los Angeles, California.

“Management of Atrial Flutter & Fibrillation in the 90s” Grand Rounds, Encino-Tarzana Medical Center. Tarzana, California.

“Management of Post MI Ventricular Arrhythmia” Lecture Program in Indonesia.

“Ventricular Arrhythmias” Golden Jubilee Celebrations of His Majesty’s Accession to the Throne, The Royal College of Physicians of Thailand. Pattaya, Thailand.

“Preoperative Evaluation of Cardiac Patients for Non-Cardiac Surgery” Golden Jubilee Celebrations of His Majesty’s Accession to the Throne, The Royal College of Physicians of Thailand. Pattaya, Thailand.

“SUDS (Sudden Unexpected Death Syndrome) in South East Asia,” “8th Annual Michel Mirowski Sudden Death Cardiac Death Symposium” Sponsored by John Hopkins University at Stouffer Harborplace Hotel. Baltimore, Maryland.

“Electrophysiology, Cardiac Arrhythmias and Treatment” Grand Rounds at Simi Valley Hospital. “Electrophysiology, Cardiac Arrhythmias and Treatment.” Simi Valley, California.

“Anticoagulation for Atrial Fibrillation: When, Where, Why and How?” Conference, Cardiac Arrhythmias: Clinical Issues and Decisions. San Diego, California.

“Sudden Unexpected Death Syndrome in Young Thai Men” 10th International Congress, Cardiostim 96. Nice, France.

“Conversion and Control of Ventricular Arrhythmias by Intravenous Antiarrhythmic Drugs” 17th Annual Scientific Sessions for NASPE. Seattle, Washington.

“Amiodarone: Oral vs. Intravenous Use” First International Symposium on Antiarrhythmic Drug Therapy. Taipei, Taiwan.

“Management of Non-ischemic Ventricular Tachycardia/Ventricular Fibrillation Arrhythmias” Cardiology Grand Rounds at Columbia University. New York, New York.

“Device Therapy for Cardiac Arrhythmias” Society for Thoracic Surgeons and the Heart Association of Thailand. Phuket, Thailand.

“Adenosine: the Molecule and Its Application: Two Days in Cardiology” Society for Thoracic Surgeons and the Heart Association of Thailand. Phuket, Thailand.

“New Era for Treating Cardiac Arrhythmias: Electrical Therapy” Symposium Chairman, August 31-September 1, 1996. Bali, Indonesia.

1997

“Recreational Drug Use and Endothelial Dysfunction” Vascular Biology Working Group, University of Florida, American College of Cardiology Sessions.

“Current Diagnosis and Treatment of Cardiac Arrhythmias” Alhambra Hospital. Alhambra, California.

“Management of Non-Coronary Ventricular Tachycardia and Ventricular Fibrillation” Electrophysiology Conference, Division of Cardiovascular Medicine, Stanford University Medical Center. Stanford, California.

“Sudden Unexplained Death Syndrome” The Council on Electrophysiology and Cardiac Pacing of the Philippine Heart Association, Philippine College of Cardiology. Manila, the Philippines.

“Management of Atrial Fibrillation” Downey Community Hospital. Downey, California

“Sudden Cardiac Death” St. Vincent’s Medical Center. Los Angeles, California

“Management of Atrial Fibrillation” University of Oklahoma Cardiology Grand Rounds. Oklahoma City, Oklahoma.

“Expanding Therapies for Common Cardiovascular Disorders: From Clinical Trials to Practice” Chair, American Heart Association 65th Annual Fall Symposium, September 10, 1997. The Omni Los Angeles Hotel, Los Angeles, California.

1998

“Advances in Electrophysiology and Cardiac Arrhythmias” Renaissance Chairman, International Symposium February 6-8, 1998. Phuket, Thailand.

“Common Cardiac Arrhythmias: Current Approaches and Therapy” Program Director, USC Division of Cardiology and Post-Graduate Division April 18, 1998 Universal City, California.

“Anticoagulation in Atrial Fibrillation” Atrial Fibrillation: Mechanisms and Management, Knoll Pharmaceutical Corporation, May 1998. Mount Olive, New Jersey.

“A New Non-Fluoroscopic Technique of Electroanatomical Mapping in Radiofrequency Ablation of Atrial Tachyarrhythmias: A Promising Advance.” Oral Presentation, NASPE Sessions, May 1998. San Diego, California.

“Unusual Syndromes with Ventricular Arrhythmias” Cardiostim 98, June 1998. Nice, France.

“New Developments in the Syndrome of Right Bundle Branch Block, ST Segment Elevation and Sudden Death: Variants and Treatment” Cardiostim 98, June 1998. Nice, France.

“Lai-Tai: Sudden Death Syndrome in Young Thai Men” Kalayanakit Kitiyakala Memorial Lecture, Faculty of Medicine, Ramthibodi Hospital, September 15, 1998. Bangkok, Thailand.

1999

Future Directions in Atrial Fibrillation Ablation, January 9-10, 1999. Dallas, Texas.

“Early Defibrillation and Chain Survival” American Heart Association Board of Directors’ Meeting, February 8, 1999, Westin Airport Hotel. Los Angeles, California.

“Ventricular Tachyarrhythmia Management” February 27, 1999. Guidant North Asia. Seoul, Korea.

“Sudden Cardiac Death in Non-Ischemic and Normal Heart” Sudden Cardiac Death Symposium, March 19, 1999, Bhumibol Adulyadej Hospital, Royal Thai Air Force. Bangkok, Thailand.

“Treatment of Atrial Fibrillation using 3-D Mapping” Heart to Heart Meeting, July 30-31, 1999. Phuket, Thailand.

“ICD in Special Subsets” 1st National Pacing, Electrophysiology and ICD Registry of Cardiological Society of India, August 20-22, 1999. New Delhi, India.

“Current Management of Atrial Fibrillation” September 17, 1999, The Queen’s Medical Center. Honolulu, Hawaii.

“ICD Electrogram Interpretation, Programming and Troubleshooting” 1st National Pacing, Electrophysiology and ICD Registry of CSI, August 20-22, 1999.

“Ventricular Tachycardia/Ventricular Fibrillation in the Normal Heart” October 26, 1999. Pacific Islands MEDPAC LLC. Papeete, Tahiti.

“Current Advances in Atrial Tachycardia Management” Pacific Islands, October 26, 1999, MEDPAC LLC. Papeete, Tahiti.

2000

Chairman “Advances in Cardiac Electrophysiology and Arrhythmia Management: Emerging Concepts for the 21st Century” February 11-13, 2000. Phuket, Thailand.

Sudden Unexpected Death Syndrome (SUDS) Cedars-Sinai Medical Center Electrophysiology Fellows Lecture Series, March 9, 2000.

Brugada’s Syndrome/Sudden Unexplained Death Syndrome, March 25, 2000. Squaw Valley, California.

“Ablation for Chronic AF” Northwest Electrophysiology Society 2000. March 31, 2000-April 2, 2000. Sun River, Oregon.

Atrial Fibrillation Discussion Group: Physician Advisory. May 16, 2000. Washington, DC.

“Atrial Fibrillation in Congestive Heart Failure” American Heart Association 68th Annual Fall Symposium, October 28, 2000. Los Angeles, California.

2001

“Sudden Cardiac Death and Brugada’s Syndrome” January 11, 2001. Department of Veterans Affairs, Department of Medicine Medical Grand Rounds, Los Angeles, California.

“Sudden Death Syndrome” March 15, 2001. University of California, San Diego, Division of Cardiology Grand Rounds. San Diego, California.

“Dilated and Hypertrophic Cardiomyopathy” March 19, 2001, American College of Cardiology 50th Annual Scientific Session. Orlando, Florida.

Core Curriculum “Catheter Ablation of VT: New Insights and Techniques” May 4, 2001 NASPE 22nd Annual Scientific Session, Boston, Massachusetts.

“Identifying Target Sites for Atrial Fibrillation Ablation”- “Heart to Heart” May 6, 2001. Biosense Webster. Laguna Beach, California.

“Management of Ventricular Tachycardia” June 13, 2001, Centinela Hospital Grand Rounds. Inglewood, California.

“Non-Pharmacological Therapy of Atrial Fibrillation” July 21, 2001, Antelope Valley Hospital, Lancaster, California

“Treatment of Atrial Fibrillation” September 4, 2001, Centinela Hospital Grand Rounds. Inglewood, California.

Electrocardiography and Arrhythmias Committee Council on Clinical Cardiology, November 12, 2001, American Heart Association 73rd Annual Scientific Sessions.

2002

“Arrhythmia Management 2002: A Program for Electrophysiology Fellows” February 26, 2002. Yountville, California.

“Diagnosis and Treatment of Common Cardiovascular Disorders: State-of-the-Art,” Program Chair, March 1-3, 2002. Vail, Colorado.

“Diagnosis and Treatment of Arrhythmogenic Right Ventricular Dysplasia and the Brugada Syndrome.” Program Chair, 23rd Annual Scientific Session of the North American Society of Pacing and Electrophysiology (NASPE), May 9, 2002. San Diego, California.

“Management of the Brugada Syndrome” May 9, 2002, 23rd Annual Scientific Session of the North American Society of Pacing and Electrophysiology (NASPE), San Diego, California.

“Sudden Death Syndrome in Young Thai Men in Asia”

“Treatment of Atrial Fibrillation” 8th Annual CME Medical Education Conference, June 22-26, 2002. Honolulu, Hawaii.

“Treatment of Atrial Fibrillation” 8th Annual CME Medical Education Conference, June 22-26, 2002. Honolulu, Hawaii.

“How to Manage Atrial Fibrillation in 2002” Panelist, American Heart Association Fall Symposium October 12, 2002. Los Angeles, California.

“Catheter Ablation of Atrial Fibrillation Substrate Guided by Electroanatomical Mapping: Favorable Outcome,” November 19, 2002, 75th Annual Scientific Sessions, American Heart Association.

2003

“Sudden Cardiac Death in Asia” XIIth World Congress on Cardiac Pacing and Electrophysiology. February 20, 2003. Invited lecturer. Hong Kong.

“Extensive Substrate Ablation for AF: Does it Work?” XIIth World Congress on Cardiac Pacing and Electrophysiology. February 21, 2003. Hong Kong.

“Ablation Therapy for AF” XIIth World Congress on Cardiac Pacing and Electrophysiology. February 21, 2003. Hong Kong.

American College of Cardiology, “Inherited Cardiac Arrhythmias and Sudden Death” April 2, 2003, Bethesda, Maryland.

North American Society of Pacing and Electrophysiology Scientific Sessions, “Interatrial Septum is the Most Common Site for Atrial Fibrillation Substrate in Humans” May 17, 2003.

Faculty, Core Curricula. “Pathophysiology and Management of Genetic Ventricular Tachyarrhythmias” May 15, 2003.

Faculty Clinical Tutorial. “Hypertrophic Cardiomyopathy, Brugada Syndrome and Inherited Channelopathies: Optimal Approach to Risk Stratification” May 15, 2003.

The Morton M. Mower, MD Cardiovascular Symposium. “Sudden Death Syndrome, Ion-Channel Defects and the Role of the Implantable Defibrillator.” Sinai Hospital of Baltimore, Johns Hopkins School of Medicine, June 12, 2003. Invited lecturer.

American Heart Association Fall Symposium 2003, “How to Manage Atrial Fibrillation in 2002” October 12, 2003. Invited Panelist. Los Angeles, California.

2004

“Brugada Syndrome” Antelope Valley Hospital, January 13, 2004. Lancaster, California.

American College of Cardiology 53rd Annual Scientific Sessions, March 7-10, 2004. Invited Speaker, Session 644, “Difficult Ventricular Tachycardia Issues Faced by Clinicians.”

68th Annual Scientific Meeting of the Japanese Circulation Society (JCS), March 27-29, 2004, Invited Speaker, “Genomic, Molecular and Clinical Aspects of Sudden Arrhythmic Death.” Tokyo, Japan.

North Texas Electrophysiology Society Grand Rounds, “Substrate Ablation of Atrial Fibrillation Patients” Invited Speaker, April 16, 2004.

“A New Approach for Catheter Ablation of Atrial Fibrillation: Mapping of the Electrophysiological Substrate” Heart to Heart, Asia Pacific Meeting, February 27, 2004. Invited Speaker. Cairnes, Australia.

“Catheter Ablation for Atrial Fibrillation: Mapping the Electrophysiologic Substrate” China CSPE Meeting, August 5-8, 2004. Guilin, PRC (China).

“Bi-Atrial Mapping and Ablation of AF Targeting Specific Substrate Regions” Toward a New Era in Interventional Electrophysiology, 3rd Annual Symposium, October 1-3, 2004, Invited Speaker, Westin Resort and Spa, Mont Tremblant, Quebec, Canada.

15th ASEAN Congress of Cardiology

2005

Tenth Annual Boston Symposium on Atrial Fibrillation, January 14-15, 2005, Invited Speaker. Seaport Hotel and Conference Center, World Trade Center, Boston, Massachusetts.

AFIB Key Opinion US Leader Meeting, January 16, 2005, Invited Participant: Round Table Discussion. Seaport Hotel and Conference Center, World Trade Center, Boston, Massachusetts

“Today’s Treatment of Atrial Fibrillation” February 22, 2005, Centinela Hospital Medical Center, Ritz-Carlton, Marina Del Rey, California.

Atrial Fibrillation Therapy Symposium, March 17-18, 2005, Invited Speaker, Hilton Hotel. Vienna, Austria.

European Cardiac Arrhythmia Society (ECAS) First Annual Congress, April 10-12, 2005, Invited Speaker. Marseille, France.

Clinical Tutorial. “Ablation for AF: Advanced Concepts” Heart Rhythm Society Scientific Sessions 2005, May 5, 2005. New Orleans, Louisiana.

Clinical Tutorial. “AF Ablation Technique Controversy” Heart Rhythm Society Scientific Sessions 2005, May 7, 2005. New Orleans, Louisiana.

Genetic Arrhythmogenic Cardiomyopathies: Debated Topics. “All patients Affected by Brugada should be submitted to EP study and receive an ICD” Pro: Koonlawee Nademanee, MD Con: Silvia Priori, XI International Symposium in Progress in Clinical Pacing, Nov 30 – Dec 3, 2005. Rome, Italy.

Ablation of Atrial Fibrillation: Long Term Results. “Long-Term Results of Fractionated Signals Guided Ablation of Atrial Fibrillation. Invited Lecturer, XI International Symposium in Progress in Clinical Pacing, Nov 30-Dec 3, 2005. Rome, Italy.

2006

Automating the Detection of Complex Fractionated Atrial Electrograms: Clinical Efficacy to Guide Catheter Ablation of AF, Invited Speaker, 11th Annual Boston Symposium on Atrial Fibrillation, January 13-14, 2006, Seaport Hotel and Conference Center, World Trade Center, Boston, Massachusetts.

Session 4.1, Anticoagulant Therapy, Invited Discussant, HIJC International Symposium, February 17-19, 2006. Toyko, Japan.

Session 6, Racial-Ethnic Differences in Sudden Cardiac Death, Invited Discussant, HIJC International Symposium, February 17-19, 2006. Toyko, Japan.

Session 6.5, SCD in Patients with Brugada Syndrome, Invited Commentator, HIJC International Symposium, February 17-19, 2006. Toyko, Japan.

Canadian Atrial Fibrillation Alliance Meeting (CAFA), April 28-29, 2006. Vancouver, Canada.

CCEP Fellows Lecture, April 13, 2006, “Fractioned Potentials & AF Ablation” Invited Lecturer, Cedars-Sinai Medical Center, Los Angeles, California

Session 74 – EP 2006, “Common Electrocardiographic Patterns: Pathophysiology and Management of Electrical Disease” “Brugada Syndrome” Presenter American College of Cardiology 55th Annual Scientific Sessions, May 11-14, 2006. Atlanta, Georgia.

Session 674 – Symposium, “Catheter Ablation of Atrial Fibrillation: Comparison of Techniques and Outcomes,” “Targeting Substrate: Electrogram-Guided Ablation” Presenter, American College of Cardiology 55th Annual Scientific Sessions, May 11-14, 2006. Atlanta, Georgia.

Session 220 – Meet the Experts, “Management of Ventricular Tachycardia/Ventricular Fibrillation Storm,” Co-Chair American College of Cardiology 55th Annual Scientific Sessions, May 11-14, 2006. Atlanta, Georgia.

“Non-Pharmacologic Treatment of Atrial Fibrillation” April 25, 2006. Invited Lecturer. San Gabriel, California.

Mini-Course, “Live and Edited Ablations of Atrial Fibrillation” May 17, 2006 Invited Presenter,Heart Rhythm Society 26th Annual Scientific Sessions, May 17-20, 2006. Boston, Massachusetts.

Clinical Tutorial, “Ablation of AF: Is There a Preferred Method?” May 18, 2006, Heart Rhythm Society 26th Annual Scientific Sessions, May 17-20, 2006. Boston, Massachusetts.

Complex Arrhythmias. “Chronic Atrial Fibrillation” Invited Lecturer, May 17, 2006, Westin Copley Place, Boston, Massachusetts.

Heart Rhythm Society Satellite Symposium, Heart Rhythm Society 26th Annual Scientific Sessions, May 17-20, 2006. Boston, Massachusetts.

Frontiers in the Treatment of Atrial Fibrillation: Applying Advanced Technologies to New Clinical Findings, “Targeting Complex Fractionated Potentials for AF Therapy: Techniques and Clinical Results” Invited Lecturer, May 18, 2006, Heart Rhythm Society 26th Annual Scientific Sessions. Boston, Massachusetts.

“Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients with Depressed Ventricular Function and Heart Failure” June 10, 2006, Vascular Leaders Summit 2006. Shanghai, China, PRC.

“Endocardial Mapping of AF Substrate: an Illusion or Reality?” June 11, 2006, Vascular Leaders Summit 2006. Shanghai, China, PRC.

“Clinical Outcomes of Catheter Ablation of Heart Failure Patients with Depressed LV Function” Boston Scientific/Guidant Fellow Dinner Lecture, August 8, 2006, Los Angeles, California.

“Non-pharmacological Treatment of Atrial Firbrillation: An Idea Whose Time has Come” September 19, 2006, The 20th Annual Kalyanakit Kitiyakara Lecture, Bangkok, Thailand.

Catheter Ablation for Atrial Fibrillation, Session 2. “Ablation Guided by CFAE” Complex Catheter Therapeutics 2006, September 21, 2006. Kobe, Japan.

Electrophysiology Live Demo, Session 1. Commentator. Complex Catheter Therapeutics 2006, September 22, 2006. Kobe, Japan.

6th International Symposium on Catheter Ablation Techniques, 7th Rhythmology Group Meeting of the French Society of Cardiology, October 12, 2006, Invited Lecturer. Paris, France.

“Management of the Patient with ICD Storm: Sympatholysis and Catheter Ablation” International Symposium on Ventricular Arrhythmia Pathophysiology & Therapy, October 14, 2006. Boston, Massachusetts.

“Substrate Based Ablation” Atrial Fibrillation: The State of The Art Cedars-Sinai Medical Center Educational Conference, October 27-29, 2006, Marina Del Rey, California.

Ablation Strategies for the Management of Atrial Fibrillation, November 10-11, 2006, Ann Arbor, Michigan.

“New Insights into Mechanism of CFAE by Point to Point Mapping” New Insights into Chronic AF (CAF) Session, 2nd Asia-Pacific Atrial Fibrillation Symposium, November 23-26, 2006, Akasaka Prince Hotel. Toyko Japan.

“Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients with Depressed Ventricular Function and Heart Failure” Treatment of AF in Heart Failure Session, 2nd Asia-Pacific Atrial Fibrillation Symposium, November 23-26, 2006, Akasaka Prince Hotel. Toyko Japan.

“Fragmented Signals in Atrial Fibrillation Mapping and Ablation” .XII International Symposium on Progress in Clinical Pacing. December 5, 2006. Rome, Italy.

2007

Boston Atrial Fibrillation Symposium, Invited Debate Participant, “Anticoagulation Can Be Safely Discontinued in Selected High Risk Patients After Attainment of Rhythm Control” Pro: Koonlawee Nademanee, MD, Con: Albert Waldo, MD, January 12, 2007. Boston, Massachusetts.

“Automating the Detection of Complex Atrial Electrograms; Clinical Efficacy to Guide Afib Ablation” Electrogram Targets in Permanent AFIB, March 8, 2007. Prague, Czech Republic.

“Ablation of Atrial Fibrillation” 71st Annual Scientific Meeting of the Japanese Circulation Society, Keynote Speaker, March 15-17, 2007. Kobe, Japan.

“Ablation of Complex Fractionated and High Frequency EGMs: When Will It Work, When Won’t It? What Does It Mean” Atrial Fibrillation Summit, May 9, 2007. Denver, Colorado.

Heart Rhythm Society 28th Annual Scientific Sessions, May 9-12, 2007. Denver, Colorado.

  • “Which Equipment? — How Can I Organize My EP Activity?” Meet-the-Experts Luncheon. May 11, 2007
  • “Targeting Complex Electrograms — Strategies for Ablation of Chronic Atrial Fibrillation” May 11, 2007
  • Electrophysiologic Observations during AF Ablations. Core Curriculum May 12, 2007

“CFAE Ablation” What is your Strategy for AF Ablation Japanese Heart Rhythm Society (JHRS), June 1-2, 2007, Hiroshima, Japan.

Core Curriculum “CFAE Ablation in AF Treatment” CAFS – China 5th Annual Afib Society Meeting, July 6-8, 2007. Beijing, China.

“Elimination of All Fragmented Atrial Potentials” June 27, 2007, Europace 2007. Lisbon, Portugal.

Sanofi Aventis Content Development Working Group for Dronedarone, August 24-25, 2007, Santa Monica, California.

“Complex Fractionated Atrial Electrograms (CFAEs), 24th Annual Meeting Japanese Society of Electrocardiology (JSE 2007), October 5, 2007, Keynote Speaker. Japan.

“Recent Progress in the Catheter Ablation Therapy of Atrial Fibrillation” 24th Annual Meeting Japanese Society of Electrocardiology (JSE 2007), October 6, 2007. Japan.

“Non-Pharmacological Treatment of Atrial Fibrillation: The Paradigm Shift” October 18, 2007, Chulalongkorn University Faculty of Medicine 60th Anniversary. Bangkok, Thailand.

Meet the Expert: CFAE Mapping and Ablation, October 19, 2007, 3rd Annual Asian Pacific Atrial Fibrillation Symposium. Taipei, Taiwan.

Moderator, Chronic AF II: Mapping and Ablation, October 19, 2007, 3rd Annual Asian Pacific Atrial Fibrillation Symposium. Taipei, Taiwan.

Adjunctive Ablation Technique – When, How, and What? October 20, 2007, 3rd Annual Asian Pacific Atrial Fibrillation Symposium. Taipei, Taiwan.

Research Activities

Major Areas of Research Interest:

  • Catheter Ablation for Treatment of Atrial Fibrillation
  • Long-term Outcome of Catheter Ablation in High-Risk Patients
  • Treatment of ICD Storm
  • Sudden Cardiac Death in Non-Structural Heart Disease (SUDS)
  • Arrhythmias and Surgical Repair of Congenital Heart Disease

Competitive Federal NIH and AHA Funded Grants

  1. Principal Investigator, Denver General Hospital NIH funded multicenter trial “A Randomized, Controlled Trial of Implantable Cardiac Defibrillators Versus Antiarrhythmic Drug Therapy in Survivors of Ventricular Tachycardia or Fibrillation (AVID) Contractor – University of Washington. 1993-1995
  2. Principal Investigator, National Institutes of Health, grant# R01 DA05485-03: “Cardiovascular Effects and Toxicities of Cocaine” 1990-1993, $820,000
  3. Principal Investigator, National Institutes of Health, grant # R01 DA05485-01: “Cardiovascular Effects and Toxicities of Cocaine” 1988-1990, $190,600
  4. Principal Investigator, American Heart Association, Greater Los Angeles Affiliate, Grant-In-Aid # 789 GI-3: “Cardiovascular Effects and Toxicities of Cocaine” 1988-1989, $20,000
  5. Co-Principal Investigator of VA Cooperative Grant “Percutaneous Transluminal Coronary Angioplasty Compared to Optimal Medical Therapy for Myocardial Ischemia” 1987-1990, $78,000
  6. Preceptor to Advanced Research Fellow, American Heart Association, Steven Khan, grant # A-AHA-LA 855 F1-1: “The Anti-Ischemic Effects of Aspirin in Unstable Angina” 1986-1987, $20,000

Bibliography

  1. Dhurandhar RW, Nademanee K, Goldman AM. Ventricular tachycardia-flutter associated with disopyramide therapy: a report of three cases. Heart Lung 1978;7:783-7.
  2. Nademanee K, Singh BN. Recent advances in drug therapy of cardiac arrhythmias. Hosp Formulary 1979;14 (part I):812-27.
  3. Nademanee K, Singh BN. Recent advances in drug therapy of cardiac arrhythmias. Hosp Formulary l979;14 (Part II):899-909.
  4. Nademanee K, Hendrickson JA, Cannom DS, Goldmeyer BN, Singh BN. control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. Am Heart J 1981;101:759-68.
  5. Melmed S, Nademanee K, Allen AW, Hendrickson JA, Singh BN, Hershman JM. Hyperthyroxinemia with bradycardia and normal thyrotropin secretin following chronic amiodarone administration. J Clin Endocrinol Metab 1981;53:997-1001.
  6. Nademanee K, Singh BN. Advances in Antiarrhythmic Therapy: The Role of Newer Antiarrhythmic Agents. JAMA 1981;247(2):217-22.
  7. Nademanee K, Singh BN, Guerrero J, Hendrickson JA, Intarachot V, Baky S. Accurate rapid compact analog method for the quantification of frequency and duration of myocardial ischemia by semiautomated analysis of 24 hour Holter ECG recordings. AM Heart J 1982;103):802-13.
  8. Singh BN, Nademanee K. New drugs in antiarrhythmic therapy. Prim Cardiol 1982;8(2)Part 1:16-32.
  9. Singh BN, Nademanee K. New drugs in antiarrhythmic therapy. Prim Cardiol l982;8(3)Part II:16-32.
  10. Kannan R, Nademanee K, Hendrickson JA, Rostami H, Singh BN. Amiodarone kinetics after oral doses. Clin Pharmacol Ther 1982;31:438-51.
  11. Nademanee K, Singh BN, Hendrickson JA, Reed A, Melmed S, Hershman JM, Reed AW, Singh BN. Pharmacokinetic significance of serum reverse t3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. Circulation 1982;66:202-11.
  12. Nademanee K, Hendrickson JA, Kannan R, Singh BN. Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. Am Heart J 1982;103:950-59.
  13. Singh BN, Hecht HS, Nademanee K, Chew CYC. Electrophysiologic and hemodynamic effects of slow channel-blocking drugs. Prog Cardiovasc Dis 1982:25:103-31.
  14. Nademanee K, Hendrickson JA, Peterson B, Cannom DS, Hecht H, Singh BN. Amiodarone: possibly an ideal antiarrhythmic agent. Am J Cardiol 1982;49;981.
  15. Nademanee K, Kannan R, Hendrickson JA, Burnam M, Kay I, Singh BN. Amiodarone digoxin interaction during treatment of resistant cardiac arrhythmias. Am J Cardiol 1982;49:1026.
  16. Singh BN, Nademanee K, The electrophysiologic classification of antiarrhythmic drugs. In Collart and Jewett, eds. Recent Developments in Cardiovascular Drugs. Edinburgh: Churchill – Livingstone; 1982:59-77.
  17. Singh BN, Nademanee K, Feld G. Calcium blockers in the treatment of cardiac arrhythmias. In Flaim SF and Zelis R, eds. Calcium Blockers: Mechanism of Action and Clinical Application. Baltimore: Urban and Schwartzenberg, 1982;245-64.
  18. Singh BN, Nademanee K, Weiss J, Wittig JH. Management of cardiac arrhythmias: a new perspective. In Shine KJ, ed. Cardiology, John Wiley and Sons, Inc., 137-176.
  19. Nademanee K, Singh B. More on amiodarone for ventricular tachyarrhythmias. N Engl J Med 1982;306:1175. Letter to the editor.
  20. Nademanee K, Singh B. Adverse effects of amiodarone. JAMA 1982;248:1448-49. Letter to the editor.
  21. Singh BN, Nademanee K, Baky SH. Calcium antagonists: clinical use in the treatment of arrhythmias. Drugs 1983;25:125-53.
  22. Nademanee K, Singh BN, Hendrickson JA, Intarachot V, Lopez B, Feld G. Amiodarone in refractory life-threatening ventricular arrhythmias. Ann Intern Med 1983;98:577-84.
  23. Singh BN, Nademanee K, Feld G. Antiarrhythmic actions of verapamil. Angiology 1983;34:572-90.
  24. Nademanee K, Hendrickson JA, Intarachot V, Hershman J, Singh BN. Significance of serum reverse T3 levels during amiodarone treatment. A potential method for monitoring chronic drug therapy. In Breithardt and Logan F, eds. New Aspects in the Medical Treatment of Tachyarrhythmias. Munich; Urban and Schwarzguberg Inc.1983:252-262.
  25. Singh BN, Nademanee K, Iked N, Kannan R. Pharmacology and electrophysiology of amiodarone: experiment and clinical correlation. In Breithardt and Logan F, eds. New Aspects in the Medical Treatment of Tachyarrhythmias: Role of Amiodarone. Munich: Urban and Schwarzguberg Inc., 1983:45-56.
  26. Singh BN, Ikeda N, Nademanee K. The comparative mechanisms of action of the electrophysiologic basis for therapeutic applications. In Gould LA, ed. Drug Treatment of Cardiac Arrhythmias. New York: Futura, 1983:1-32.
  27. Singh BN, Ellrodt G, Nademanee K. Calcium antagonists: Cardiocirculatory effects therapeutic applications. In Hurst JW, ed. Clinical Essays on the Heart. McGraw-Hill, 1983:65-98.
  28. Nademanee K, Singh BN, Cannom DS, Weiss J, Feld G. Stevenson WE. Control of sudden recurrent arrhythmic deaths: role of amiodarone. Am Heart J 1984;106:895-901.
  29. Singh BN, Nademanee K. Amiodarone and thyroid function: clinical implication during antiarrhythmic therapy. Am Heart J 1984;106:857-69.
  30. Nademanee K, Kannan R, Hendrickson JA, Ookhtens M, Kay I, Singh BN. Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms, and therapeutic implications. J Am Coll Cardiol 1984;7:111-16.
  31. Feld G. Nademanee K, Weiss J. Stevenson W, Singh BN. Electrophysiologic basis for the suppression of orthodromic supraventricular tachycardia complicating preexcitation syndromes. J Am Coll Cardiol 1984;3:1298-1307.
  32. Nademanee K, Schleman MM, Singh BN, Morganroth, Reid PR, Stritar JA. Beta adrenergic blockade by nadolol in control of ventricular tachyarrhythmias. Am Heart J 1984;108:1109-15.
  33. Ikeda N, Nademanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: experimental and clinical observations relative to serum and tissue drug concentrations. Am Heart J 1984;108:890-8.
  34. Singh BN, Nademanee K, Kannan R, Ikeda N. The clinical results of amiodarone in cardiac arrhythmias: optimal dosing. Pace 1984;7:109-24.
  35. Singh BN, Nademanee K, et al. Recent trends in the management of life-threatening ventricular arrhythmias. West J Med l984;141:649-65.
  36. Singh BN, Nademanee K, Josephson M, Ikeda N, Venkatesh N, Kannan R. The electrophysiology and pharmacology of verapamil, flecainide, and amiodarone: correlations with clinical effects and antiarrhythmic actions. Garfein OB, ed. In Clinical Pharmacology of Cardiac Antiarrhythmic Agents. Ann NY Acad Sci l984;210-35.
  37. Singh BN, Nademanee K. Pharmacological control of ventricular arrhythmias in survivors of acute myocardial infarction: the role of nine antiarrhythmic agents. In Post Vyden JK, Ed. Myocardial Infarction Management and Rehabilitation. New York: Marcel Dekker, 1984:175-99.
  38. Singh BN, Nademanee K, Schwab M. The role of calcium antagonists in the emergency control of cardiac arrhythmias. In Rund DA and Wolcott BW, eds. Emergency Medicine Annual. Connecticut: Appleton-Century-Corps, 1984:183-205.
  39. Singh BN, Nademanee K, Ikeda N, Hendrickson JA, Kannan R, Feld G. Antiarrhythmic actions of compounds that prolong the action-potential duration of cardiac muscle, including bretylium and amiodarone. In Benedict R, Lucchesi, Dingell JV, Schwartz RP, eds. Clinical Pharmacology of Antiarrhythmic Therapy. New York: Raven Press, 1984:105-26.
  40. Nademanee K, Schleman MM, Singh BN, Morganroth, Reid PR, Stritar JA. Beta adrenergic blockade by nadolol in control of ventricular tachyarrhythmias. Am Heart J 1984;108:1109-15.
  41. Ikeda N, Nademanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: experimental and clinical observations relative to serum and tissue drug concentrations. Am Heart J 1984;108:890-98.
  42. Singh BN, Nademanee K, Kannan R, Ikeda N. The clinical results of amiodarone in cardiac arrhythmias: optimal dosing. PACE 1984;7:109-24.
  43. Singh BN, Nademanee K, et al. Recent Trends in the Management of Life-Threatening Ventricular Arrhythmias. West J Med l984;141:649-65.
  44. Singh BN, Nademanee K, Josephson M, Ikeda N, Venkatesh N, Kannan R. The electrophysiology and pharmacology of verapamil, flecainide, and amiodarone: correlations with clinical effects and antiarrhythmic actions. In Garfein OB, ed. Clinical Pharmacology of Cardiac Antiarrhythmic Agents. Ann NY Acad Sci l984;210-35.
  45. Nademanee K, Feld G, Noll E, Hendrickson JA, Singh BN. Effect of sotalol, class III antiarrhythmic agent, on conduction and refractoriness of the His-Purkinje system in man. J Am Coll Cardiol 1985;5:438.
  46. Singh BN, Kannan R, Nademanee K, Venkatesh N. Newer antiarrhythmic agents and the elderly patient. In Coodley El, ed. Geriatric Heart Disease. PSG Publishing Co., 1985:377-91.
  47. Singh BN, Nademanee K, Control of arrhythmias by lengthening cardiac repolarization: unique role of sotalol. In Sami M, ed. Advances in Cardiology: the Unique Role of Sotalol. Medicine Publishing Symposium Series, 1985; 17:15-29.
  48. Nademanee K, Hendrickson JA, Heng M, Lopez B, Feld G. Singh BN. Mexiletine: double-blind comparison with procainamide in premature ventricular contraction suppression and open-label sequential comparison with amiodarone in life-threatening ventricular tachycardia. Am Heart J 1985;110:923-31.
  49. Singh BN, Nademanee K. Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations. Am Heart J 1985;109:421-30.
  50. Singh BN, Baky S, Nademanee K. Second generation calcium antagonists: search for greater selectivity and versatility. Am J Cardiol 1985;55:214b.
  51. Singh BN, Nademanee K, Feld G, Piontek M, Schwab M. Comparative electrophysiologic profiles of calcium antagonists with articular reference to bepridil. electrophysiologic profiles of calcium antagonists with particular reference to bepridil. Am J Cardiol 1985;55:14c-19c.
  52. Nademanee K, Feld G, Hendrickson JA, Singh PN, Singh BN. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 1985;72;555-64.
  53. Nademanee K, Hendrickson JA, Heng M, Lopez B, Feld G. Singh BN. Mexiletine: double-blind comparison with procainamide in premature ventricular contraction suppression and open-label sequential comparison with amiodarone in life-threatening ventricular tachycardia. Am Heart J 1985;110:923-31.
  54. Singh BN, Nademanee K. Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations. Am Heart J 1985;109:421-30.
  55. Singh BN, Baky S, Nademanee K. Second generation calcium antagonists: search for greater selectivity and versatility. Am J Cardiol 1985;55:214b.
  56. Singh BN, Nademanee K, Feld G, Piontek M, Schwab M. Comparative Electrophysiologic profiles of calcium antagonists with particular reference to bepridil. Electrophysiologic profiles of calcium antagonists with particular reference to bepridil. Am J Cardiol 1985;55:14c-19c.
  57. Nademanee K, Feld G, Hendrickson JA, Singh PN, Singh BN. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 1985;72;555-64.
  58. Mangiardi L, Gaita F, Brun S, Presbitero P, Nademanee K, Singh BN. Atrioventricular block complicating amiodarone-induced hypothyroidism in a patients with pre-excitation and rate-dependent bilateral bundle branch block.. J Am Coll Cardiol 1986;7:180-84.
  59. Hershman JM, Nademanee K, Sugawara M, Masahiro S, Pekary AE, Ross R, Singh BN, DeStefano JJ III. Thyroxine and triiodothyronine kinetics in cardiac patients taking amiodarone. Acta Endrocrinol 1986;111:193-9.
  60. Singh BN, Nademanee K, Figueras J, Josephson MA. Hemodynamic and electrocardiographic correlates of symptomatic and silent myocardial ischemia: pathophysiologic and therapeutic implications. Am J Cardiol 1986;58:3b-10b.
  61. Nademanee K, Intarachot V, Singh PN, Josephson MA, Singh BN. Characteristics and clinical significance of silent myocardial ischemia in unstable angina. Am J Cardiol 1986;58:26b-87b.
  62. Singh BN, Rebanal P, Piontek M, Nademanee K. Calcium antagonists and betablockers in the control of mild to moderate hypertension, with particular reference to verapamil and propranolol. Am J Cardiol 1986;57:99d-105d.
  63. Singh BN, Nademanee K. Beta-adrenergic blockade in unstable angina pectoris. Editorial. Am J Cardiol 1986;57:992-94.
  64. Singh BN, Nademanee K, Josephson MA. Newer concepts of pathogenesis of myocardial of ischemia: implication for the evaluation of anti-anginal therapy. Drugs 1986;32:1-14.
  65. Nademanee K, Singh BN, Callahan B, Hendrickson JA, Hershman JM. Amiodarone, thyroid hormone indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias. Am J Cardiol 1986;58:980-6.
  66. Singh BN, Feld GK, Nademanee K. Arrhythmia control by selective lengthening of cardiac repolarization: role of N-acetylprocainamide, active metabolite of procainamide. Angiology J Vasc Dis 1987;37:929-38.
  67. Singh BN, Nademanee K. Prevalence and Prognostic Significance of Silent Myocardial Ischemia in Patients with Unstable Angina. Circulation 1987;75(suppl II):II-40-1.
  68. Feld GK, Nademanee K, Singh BN, Kirsten E. Hemodynamic and electrophysiologic effects of combined infusion of lidocaine and propafenone in humans. J Clin Pharmacol 1987;27:52-9.
  69. Nademanee K, Intarachot V, Josephson MA, Rieders D, Mody Vaghaiwalla F, Singh BN. Prognostic significance of silent myocardial ischemia in patients with unstable angina. J Am Coll Cardiol 1987;10:1-9.
  70. Singh BN, Nademanee K. Sotalol; a beta-blocker with unique antiarrhythmic properties. Am Heart J 1987;114:121-39.
  71. Singh BN, Nademanee K, Use of calcium antagonists for cardiac arrhythmias. Am J Cardiol 1987;59:153b-62b.
  72. Josephson MA, Nademanee K, Intarachot V, Lewis H, Singh BN. Abolition of Holter-detected silent myocardial ischemia after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1987;10:499-503.
  73. Nademanee K, Intarachot V, Josephson MA, Singh BN. Circadian variation in the occurrence of transient overt myocardial ischemia in chronic stable angina: comparison with Prinzmetal angina in man. Am J Cardiol 1987;60:494-8.
  74. Singh BN, Nademanee K, Josephson MA. Hemodynamic and ECG correlates of silent ischemia. J Angina Silent Ischemia 1987;2:16-20.
  75. Nademanee K, Singh BN. Characterization of silent ischemia in patients with unstable angina: prognostic and therapeutic implications. Herz 1987;12:328-35.
  76. Nademanee K, Lockhart E, Pruitt C, Singh BN. Cardiac electrophysiologic effects of intravenous ketanserin in man. J Cardiovasc Pharmacol 1987;2:32-7.
  77. Singh BN, Nademanee K. Antihypertensive compounds as antiarrhythmic agents: focus on beta-blocking drugs in ventricular arrhythmias. Am Heart J 1987;114:1040-50.
  78. Singh BN, Deedwania P, Nademanee K. Sotalol: a review of pharmacodynamic properties and therapeutic uses. Drugs l987;34:311-49.
  79. Control of Cardiac Arrhythythmic effects of sotalol with particular reference to the control of ventricular arrhythmias. In Singh BN, ed. Controlling Cardiac Arrhythmias by Lengthening Repolarization. Mount Kisco, NY: Futura Publishing Co., 1988:209-44.
  80. Stevenson W, Rieders D, Nademanee K, Weiss J, Singh BN. Amiodarone in the management of supraventricular tachycardias. In Singh BN, ed. Controlling Cardiac Arrhythmias by Lengthening Repolarization. Mount Kisco, NY: Futura Publishing Co., 1988:419-33.
  81. Nademanee K, Stevenson W, Weiss J, and Singh BN. The role of amiodarone in the survivors of sudden arrhythmic death. In Singh BN, ed. Controlling Cardiac Arrhythmias by Lengthening Repolarization. Mount Kisco, NY: Futura Publishing Co., Mount Kisco, 1988:489-508.
  82. Nademanee K, Singh BN. Silent myocardial ischemia as an index of adverse prognosis in patients with unstable angina. In Singh BN, ed. Silent Myocardial Ischemia and Angina. New York: Pergamon Press, 1988:147-56.
  83. Nademanee K. Reproducibility of ischemic parameters: relevance to the choice of therapeutic and points. In Singh BN, ed. Silent Myocardial Ischemia and Angina. New York: Pergamon Press, 1988;223-34.
  84. Singh BN, Nademanee K. Calcium antagonists and beta-blockers, alone and in combination, in the suppression of silent myocardial ischemia in chronic stable angina. In Singh BN, ed. Silent Myocardial Ischemia and Angina. New York: Pergamon Press, 1988:272-83.
  85. Stevenson WG, Weiss JN, Wiener I, Nademanee K, Wohlgelernter D, Yeatman L, Josephson MA, Klitzner T. Resetting of ventricular tachycardia: implications for localizing the area of slow conduction. J Am Coll Coll 1988;11:522-9.
  86. Nademanee K. Circadian variation of transient myocardial ischemia: chronic stable angina vs Prinzmetal’s angina. J Ang Silent Ischemia 1988;3:5-7.
  87. Feld GK, Nademanee K, Stevenson W, Weiss J, Klitzner T, Singh BN. Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation or flutter complicating the Wolff-Parkinson-White Syndrome. Am Heart J 1988;115:102-7.
  88. Vaghaiwalla Mody F, Nademanee K, Intarachot V, Josephson MA, Robertson HA, Singh BN. Severity of silent myocardial ischemia on ambulatory lectrocardiographic monitoring in patients with stable angina pectoris: relations to prognostic determinants during exercise stress testing and coronary angiography. J Am Coll Cardiol 1988;12:1169-76.
  89. Nademanee K, Singh BN. Control of cardiac arrhythmias by calcium antagonism. Ann NY Acad Sci l988;522:536-52.
  90. Nademanee K, Singh BN. Pharmacology and clinical use of sotalol as an antiarrhythmic agent. Pract Cardiol l988;14:67-80.
  91. Nademanee K, Christenson PD, Intarachot V, Robertson HA, Vaghaiwalla Mody F. Variability of parameters of myocardial ischemia: a comparison of exercise treadmill test, ambulatory electrocardiographic monitoring, and symptoms of myocardial ischemia. J Am Coll Cardiol 1989;13:574-9.
  92. Feld G, Nademanee K, Noll E, Singh B. Oral N-acetylprocainamide compared to quinidine plus digoxin in the chronic suppression of atrial flutter in man. Cardiovasc Drugs Ther 1989;3:191-198.
  93. Stevenson G, Weiss J, Wiener I, Rivitz SM, Nademanee K, Klitzner T, Yeatman L, Josephson M, Wohlgelernter D. Fractionated endocardial electrograms are associated with slow conduction in Humans: Evidence from pace mapping. J Am Coll Cardiol 1989;13:369-76.
  94. Stevenson G, Weiss J, Wiener I, Nademanee K. Slow conduction in the infarct scar: relevance to the occurrence, detection, and ablation of ventricular reentry circuits resulting from myocardial infarction. Am Heart J 1989;117:452-67.
  95. Nademanee K, Gorelick D, Josephson MA, Ryan MA, Wilkins JN, Robertson H, Mody F, Intarachot V. Myocardial ischemia during cocaine withdrawal. Ann Intern Med 1989;111:876-80.
  96. Stevenson WG, Nademanee K, Weiss JN, Wiener I, Baron K, Yeatman LA, Sherman T. Programmed electrical stimulation of sites in ventricular reentry circuits: comparison of predictions from computer simulations with observations in humans Circulation 1989;80;793-806.
  97. Singh B, Venkatesh N, Nademanee K, Josephson M, Kannan R. The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis 1989;31:249-80.
  98. Nademanee K, Piwonka RW, Singh BN, Hershman JM. Amiodarone and thyroid function. Prog Cardiovasc Dis 1989;31:427-37.
  99. Nademanee K. What is cocaine-induced heart disease? Choices in Cardiology 1989;3:180-182.
  100. Nademanee K, Singh BN: Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents. Am J Cardiol 1990;65:53 A-57A.
  101. Nademanee K, Stevenson WG, Weiss JN, Frame VB, Antimisiari MG, Suithichaiyakul T, Pruitt CN Frequency-dependent effects of quinidine on ventricular action potential and QRS duration in man. Circulation 1990;81;790-6.
  102. Wiener I, Stevenson WG, Weiss J, Nademanee K. Are electrophysiologic studies indicated in patients with nonsustained ventricular tachycardia? Am J Cardiol 1990;66:642-4.
  103. Stevenson WG, Nademanee K, Weiss JN, Wiener I. Treatment of catecholamine sensitive right ventricular tachycardia by endocardial catheter ablation. J Am Coll Cardiol 1990;16:752-755.
  104. Nademanee K. A tale of the spontaneous variability of premature ventricular contractions. Circulation 1990;82:1054-7.
  105. Weiss JN, Nademanee K, Stevenson WG, Singh B. Ventricular arrhythmias in ischemic heart disease. Ann Intern Med 1991;114:784-97.
  106. Nademanee K. The amiodarone-class I agent combination increase refractoriness, conduction, and the number of electrophysiologic studies: but does it increase survival rate? Circulation 1991;84:429-31.
  107. Wesley RC, Taylor R, Nademanee K. Catecholamine-sensitive right ventricular tachycardia in the absence of structural heart disease: a mechanism of exercise induced cardiac arrest. Cardiology 1991.
  108. Nademanee K, Refractory Ventricular Fibrillation in the Electrophysiology Laboratory: A Nightmare From Which We Can Awaken. J Am Coll Cardiol 1991;18:1285-6.
  109. Nademanee K. The cardiovascular toxicity of cocaine. Prim Cardiol 1991;17(3):40-49.
  110. Parisi A, Folland E, Hartigan P, on behalf of the Veterans Affairs ACME Investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992;326:10-6.
  111. Nademanee K. Cardiovascular effects and toxicities of cocaine. J Addictive Dis 1992;11:71-82.
  112. Nademanee K. The amiodarone odyssey. J Am Coll Cardiol 1992;20:1063-5.
  113. Stevenson WG, Sager P, Nademanee K, Hassan H, Middlekauff HR, Saxon LA, Wiener I. Identifying sites for catheter ablation of ventricular tachycardia. Herz 1992;17:158-70.
  114. Sager P, Nademanee K, Antimisiaris M, Pacifico A, Pruitt C, Godfrey R, Singh B. The antiarrhythmic effects of selective prolongation of refractoriness: electrophysiologic action of sematilide HCl in humans. Circulation 1993;88:1072-82.
  115. Nademanee K, Singh B, Stevenson W, Weiss J. Amiodarone and post-MI patients. Circulation 1993;88:764-74.
  116. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
  117. Mittleman M, et al. and the Myocardial Infarction Onset Study Investigators. Triggering of Acute Myocardial Infarction by Heavy Physical Exertion. New Engl J Med 1993:329:1677-83.
  118. Read R, Moore E, Moore F, Nademanee K, Havranek E, Veerakul G, Mestek M. Intravascular Ultrasound (IVUS) for the Diagnosis of Traumatic Aortic Disruptions. A case report. Surgery 1993;114:624-8.
  119. The AVID Investigators: Antiarrhythmics Versus Implantable Defibrillators (AVID)-rationale, design, and methods. Am J Cardiol 1995;75:470-5.
  120. Mahonada N, Bhuripanyo K, Kangkagate C, Wansanit K, Kulchot B, Nademanee K, Chaithiraphan S. Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. Am Heart J 1995:130;1250-3.
  121. Sung H, Sager PT, Stevenson WG, Nademanee K, MiddleKauff R, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
  122. Glasser SP, Ripa S, Garland WT, Weiss R, Nademanee K, Singh B, Bittar N. Antianginal and antiischemic efficacy of monotherapy extended-release nisoldipine (coat core) in chronic stable angina. J Clin Pharmacol 1995;35:780-4.
  123. Raungratanaamporn O, Nutakul T, Hongvisitgul C, Bhuripanyo K, Nademanee K, Chaithiraphan S. Radiofrequency catheter ablation in idiopathic ventricular tachycardia with structurally normal heart. J Med Assoc Thai 1995:78:227-34.
  124. Nademanee K, Noll EH, Feld GK. Effects of Sotalol on His-Purkinje conduction and refractoriness in humans. J Card Pharm Therap 1996;1:9-16.
  125. Hopson JR, Buxton AE, Rinkenberger RL, Nademanee K, Heilman JM, Kienzle MG. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. Am J Cardiol 1996;77:72A-82A.
  126. Bhuripanyo K, .Laksanabunsong P, Raungratanaamporn O, Nutakul T. Nademanee,K Chaithiraphan S. Successful implantation of transvenous automatic implantable cardioverter defibrillator (AICD): The first case report in Thailand. J Med Assoc Thai 1996;79:536-40.
  127. Havranek, EP. Nademanee,K. Grayburn,PA,Eichhorn, EJ. Endothelium-dependent vasorelaxation is impaired in cocaine arteriopathy. J Am Coll Cardiol 1996;28:1168-74.
  128. Lu RM, Steinhaus BM, Bailey W, Nademanee K. Clinical significance of a new P wave lead vector for pacemaker follow-up of atrial functions. PACE 1996;19:1805-8.
  129. Nademanee, K. Sudden unexplained death syndrome in Southeast Asia. Am J Cardiol 1997;70:10-11.
  130. Nademanee K, Veerakul G, Nimmannit S, Chaowakul V, Bhuripanyo Likittanasombat K, Tunsanga K, Kuasirikul S, Malasit P,Tansupasawadikul S, Tatsanavivat P. An arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997;96:2595-600.
  131. Nademanee K, Kosar E. A non-fluoroscopic catheter-based mapping technique to ablate focal ventricular tachycardia. PACE 1998;21:1442-7.
  132. Nademanee K, Kosar E. Long-Term Anti-thrombotic Treatment for Atrial Fibrllation. Am J Cardiol 1998;82:37N-42.
  133. N. Grant, A.O., Reiffel, J.A., Winters, S., Page, R., Webb, C., Kutalek S, Nademanee K, Olshansky B, Carlson M, Ferrick K. Data Driven Decisions – Picking the Correct Agent. Discussion. Am J Cardiol 1998;82 Suppl 8A:80N-81N.
  134. Olshansky B, Luderitz B, Falk RH, Nademanee K, Winters S. Rate Issues: Consequences and Therapy: Discussion. Am J Cardiol 1998;82:Suppl 8A:35N-36N.
  135. Antzelevitch C, Brugada P, Brugada J, Brugada R, Nademanee K, Towbin J. In Camm, JA, ed.” Clinical Approaches to Tachyarrhythmias:” Volume 10.
  136. The Brugada Syndrome. Armonk, NY: Futura Publishing Company; 1999.
  137. Nademanee K, Bhuripanyo K, Krittayapong R, Kosar E, McKenzie J, Mehra A, Rieders D, Schwab M. “Maintaining sinus rhythm in patients with atrial fibrillation using the modified catheter maze ablation” Submitted Circulation May 1999.
  138. Mattioni T, Nademanee K, Bodsky M, Fisher J, Riggio D, Allen B, Welch S, Ybarra R, Lin D, Dean E. “Initial clinical experience with a fully automatic in-hospital external cardioverter defibrillator.” PACE 1999;22:1648-55.
  139. Khongphatthanayothin A, Kosar E, Nademanee K. Non-fluoroscopic three-dimensional mapping for arrhythmia ablation: tool or toy? J Cardiovasc Electrophysiol 2000;11:239-43.
  140. Veerakul G., Nademanee K. What is the sudden death syndrome in Southeast Asian males? Cardiol Rev 2000;8:90-5.
  141. Nademanee K, Taylor R, Bailey W, Rieders D, Kosar E. Treating Electrical Storm: Sympathetic Blockade versus Advanced Cardiac Life Support-Guided Therapy. Circulation 2000;102:742-7.
  142. Nademanee K. Prognostic value of electrophysiologic studies in Brugada syndrome. J Am Coll Cardiol 2002;39:1806-7.
  143. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer RN, Kass RS, Nademanee K, Priori SG. “Proposed Diagnostic Criteria for the Brugada Syndrome” Eur Heart J 2002;23:1648-54.
  144. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer R, Kass R, Nademanee K, Priori S, Towbin J. The Study Group on the Molecular Basis of Arrhythmias of European Society of Cardiology. Mini-Review: Current Perspective. Circulation 2002;106:2514-2519.
  145. Vatta M, Dumaine R, Barghese G, Richard T, Shimizu W, Aihara N. Nademanee K, et al. Genetic and Biophysical Basis of Sudden Unexplained Nocturnal Death Syndrome (SUNDS), a Disease Allelic to Brugada Syndrome. Human Molecular Genetics, 2002. Vol. 11, No 3.
  146. Brugada J, Brugada R, Antzelevitch C, Towbin J. Nademanee K. Brugada P “Long-Term Follow-up of Individuals with the Electrocardiographic Pattern of Right Bundle-Branch Block and ST-Segment Elevation in Precordial Leads V1 to V3. Circulation 2002;105:78-8.
  147. Krittayaphong R, Veerakul G, Bhuripanyo K, Jirasirirojanakorn K, Nademanee K. Heart Rate Variability in Patients with sudden unexplained cardiac arrest in Thailand. Am J Cardiol 2003;91:77-81.
  148. Antzelevitch C, Brugada P, Brugada J, Brugada R, Towbin JA Nademanee K. “Brugada Syndrome: 1992-2002: A Historical Perspective.” Review. J Am Coll Cardiol 2003;41:1665-71.
  149. Nademanee K. Veerakul G. Mower M. Likittanasombat K, Krittayapong R. et al. Defibrillator vs. Beta-blockers for Unexplained Death in Thailand (DEBUT). A randomized clinical trial. Circulation 2003;107:2221-6.
  150. Nademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul T, Khunnawat C, Ngarmukos T. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiological substrate. J Am Coll Cardiol 2004;43:2044-53.
  151. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A. Brugada syndrome: report of the second consensus conference. Heart Rhythm 2005;2:429-40.
  152. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005;111:659-70.
  153. Daoud EG, Nademanee K, Fuenzalida C, Tomassoni GF, Schuger C, Chisner M, Simones M, Schwartz M, Reeve H. Clinical experience with tiered atrial therapies and atrial arrhythmia prevention algorithms in a dual chamber cardioverter defibrillator. J Cardiovasc Electrophysiol 2006;17:852-6.
  154. Nademanee K, Schwab M, Porath J, Abbo R. How to perform electrogram guided atrial fibrillation ablation. Heart Rhythm 2006;3:981-4.
  155. Nademanee K. Is pulmonary vein isolation by segmental ostial ablation a correct approach for treatment of atrial fibrillation? Heart Rhythm 2006;3:1029-30.
  156. Neelagaru SB, Sanchez JE, Lau SK, Greenberg SM, Raval NY, Worley S, Kalman J, Merliss AD, Krueger S, Wood M, Wish M, Burkhoff D, Nademanee K. Nonexcitatory cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm 2006;3:1140-7.
  157. Nademanee K. Percutaneous epicardial catheter ablation opens another chapter in the catheter-based ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2007;18:924-5.
  158. Nademanee K. Trials and travails of electrogram-guided ablation of chronic atrial fibrillation. Circulation. 2007;115:2592-4.
  159. Nademanee K, Schwab MC, Kosar EM, Karwecki M, Moran MD, Visessook N, Don Michael A, Ngarmukos T. Mortality and Stroke Reduction after Successful Catheter Substrate Ablation for High Risk Patients with Atrial Fibrillation. J Am Coll Cardiol 2008; In Press.
  160. Nademanee K, Schwab M, Porath J, Abbo R. How to perform electrogram guided atrial fibrillation ablation. Catheter Ablation of Cardiac Arrhythmias: Basic Concepts and Clinical Applications. Third Edition, Blackwell Futura; 250-261.

Abstracts

  1. Melmed S, Nademanee K, Reed AW, Hendrickson JA, Singh BN, Hershman JM. Evaluation of pituitary-thyroid axis in patients receiving amiodarone: hyperthyroxinemia with bradycardia and normal TSH secretion. Presented at the Meeting of the Program of the American Thyroid Association, San Diego, California, November 6-8, 1980.
  2. Nademanee K, Hendrickson JA, Cannom DS, Singh BN. Refractory life-threatening ventricular arrhythmias: controlled by amiodarone prophylaxis. Circulation 1980;62(suppl):573.
  3. Nademanee K, Melmed S, Hendrickosn JA, Reed AW, Hershman JM, Singh BN. Role of serum T4 and reversed T3 in monitoring of amiodarone in resistant arrhythmias. Presented at the Annual Scientific Meeting of the American Heart Association, Dallas, Texas, November 16-19, 1981.
  4. Kannan R, Nademanee K, Hendrickson JA, Rostami H, Singh BN Plasma levels of amiodarone and its elimination half-life following acute and chronic dosing in patients with ventricular arrhythmias. Presented at the Annual Scientific Meeting of the American Heart Association, Dallas, Texas November 16-19, 1981.
  5. Nademanee K, Cannom DS, Hendrickson JA, Goldmeyer B, Singh BN. Recurrent sudden arrhythmic cardiac deaths prevented by amiodarone: efficacy predictable by the initial suppression of ventricular tachyarrhthmias. Presented at the Annual Scientific Meeting of the American Heart Association, Dallas Texas, November 16-19, 1981.
  6. Nademanee K, Hendrickson JA, Peterson B, Cannom DS, Hecht H, Singh BN. Amiodarone: possibly an ideal antiarrhythmic agent. Am J Cardiol 1982;49:981.
  7. Nademanee K, Kannan R, Hendrickson JA, Burnam M, Kay I, Singh BN. Amiodarone digoxin interaction during treatment of resistant cardiac arrhythmias. Am J Cardiol 1982;49:1026.
  8. Nademanee K, Singh BN, Intarachot V, Lopez B, Hendrickson JA, Guerrero J. Compact analog Holter analysis of transient myocardial ischemia in unstable angina: clinical significance and therapeutic implications. Presented at the 35th Annual Scientific Sessions of the American Heart Association, Dallas Texas, November 15-18, 1982.
  9. Nademanee K, Hendrickson JA, Heng M, Lopez B, Feld G, Singh BN. Mexilentine: double-blind comparison with procainamide in premature ventricular contraction suppression and open-labeled comparison with amiodarone in refractory ventricular tachycardia. Presented at the 55th Annual Scientific Session of the American Heart Association, Dallas, Texas, November 15-18, 1982.
  10. Nademanee K, Singh BN, Hendrickson JA, Rollett E. Efficacy of three beta-antagonists in suppression of premature ventricular contraction: relevance to mechanism of sudden death reduction in survivors of myocardial infarction. Presented at the American College of Cardiology Scientific Session, New Orleans, Louisiana, March 20-24, 1983.
  11. Nademanee K, Feld G, Hendrickson JA, Intarachot V, Kannan R, Singh BN. Does intravenous amiodarone shorten the latency of the onset of anti-arrhythmic action of oral amiodarone in ventricular dysrhythmia? Presented at the American College of Cardiology Scientific Session, New Orleans, Louisiana, March 20-24, 1983.
  12. Feld G, Nademanee K, Weiss J, Hendrickson JA, Singh BN. Oral amiodarone in patients with AV nodal and bypass tract re-entrant supraventricular tachycardia: electrophysiology and mechanism of suppression of inducible tachycardia. Presented at the American College of Cardiology Scientific Session, New Orleans, Louisiana, March 20-24, 1983.
  13. Nademanee K, Hendrickson JA, Cannom DS, Goldmeyer BN, Singh BN. Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. Cardiology Digest, October 1982.
  14. Nademanee K, Feld G. Hendrickson JA, Intarachot V, Singh BN. Electrophysiology and antiarrhythmic effects of sotalol in patients with refractory life-threatening tachyarrhythmias. Circulation 1983;68(suppl II):II-271.
  15. Nademanee K, Kannan R, Wagner R, Intarachot V, Hendrickson JA, Singh BN. Role of amiodarone, desethylamiodarone, and reverse T3 serum levels in monitoring antiarrhythmic efficacy and toxicity: sensitivity of rT3 and desethylamiodarone levels. Circulation 1983;68(suppl II):II-278.
  16. Nademanee K, Inarachot V, Singh BN. Compact analog Holter analysis of transient myocardial ischemia in exercise-induced angina; a significant technique for monitoring and guiding antianginal therapy. Circulation 1083;68(suppl III).
  17. Nademanee K, Singh BN, Piontek M, Intarachot V, Yale C. Antianginal efficacy of bepridil, an novel calcium antagonist: double-blind evaluation by quantitating myocardial ischemia by compact Holter analog technique in chronic stable angina.Presented at the American College of Cardiology Scientific Session, Dallas, Texas, March 25-29, 1984.
  18. Nademanee K, Feld G, Hendrickson JA, Intarachot V, Singh BN: Role of intravenous amiodarone in the acute control of supraventricular tachyarrhythmias. Presented at the American College of Cardiology Scientific Session, Dallas, Texas, March 25-29, 1984.
  19. Nademanee K, Intarachot V, Piontek M, Mody Vaghaiwalla F, Rieders D, Josephson M, Singh BN: Silent myocardial ischemia on Holter: has it clinical or prognostic significance. Circulation 1984;70:(suppl II):II-451.
  20. Nademanee K, Intarachot V, Piontek M, Mody Vaghiwalla F, Josephson M, Singh BN. Relationship of myocardial ischemia detected by compact Holter analog technique to that induced by ETT. Circulation 1984;70(suppl II):II-45.
  21. Nademanee K, Feld G, Noll E, Hendrickson JA, Singh BN. Effect of sotalol, class III antiarrhythmic agent, on conduction and refractoriness of the His-Purkinje system in man. J Am Coll Cardiol 1985;5:438.
  22. Nademanee K, Kannan R, Feld G, Hendrickson JA, Miller S, Singh BN: Sotalol in malignant ventricular arrhythmias: role of programmed electrical stimulation, Holter monitoring, and serums sotalol levels in predicting long term clinical outcome. Circulation 1985;75(suppl III):III-171.
  23. Nademanee K, Callahan B, Hendrickson JA, Hershman JM. Amiodarone and thyroid disorders: a longitudinal study. Circulation 1985;72(suppl III):III-273.
  24. Nademanee K, Intarachot V, Hendrikson JA, Josephson M, Singh BN. Diurnal variation in occurrence of transient myocardial ischemia documented by compact analog analysis of Holter recording: differences between chronic stable and Prinzmental angina. J Am Coll Cardiol 1986;7:191A.
  25. Josephson MA, Lewis HS, Nademanee K, Intarachot V, Coule K, Singh BN. Abolition of Holter-detected silent myocardial ischemia following percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1986;7:191A.
  26. Nademanee K, Lee IK, Singh BN. Sotalol versus procainamide in the prevention of ventricular tachycardia induction: a double-blind parallel multicenter study. Presented at the American Heart Assoc. 59th Scientific Sessions, Dallas Texas, November 1986.
  27. Stevenson WG, Weiss JN, Wiener I, Nademanee K, Wohlgelernter D, Yeatman L, Josephson M. Entrainment as a guide for localizing the site of ventricular tachycardia. J Am Coll Cardiol 1987;9:153A.
  28. Khan S, Gorelick D, Nademanee K, Singh BN. Effects of alcohol on diurnal heart rate variation. J Am Coll Cardiol 1987;9:225A.
  29. Stevenson WG, Rivitz SM, Wiener I, Weiss JN, Nademanee K, Klitzner T, Yeatman L, Wohlgelernter D. Do fractionated electrograms indicate slow conduction? Circulation 1987;76(suppl IV):IV-83.
  30. Mody G, Nademanee K, Intarachot V, Josephson MA, Robertson H. Harwood B, Singh BN. Prognostic significance of silent myocardial ischemia in chronic stable angina based on correlation with coronary angioplasty. Circulation 1987;76(suppl IV):IV-78.
  31. Feld G, Nademanee K, Noll HE, Singh BN. N-acetylprocainamide versus quinidine and digoxin in the chronic suppression of atrial flutter in man. Circulation 1987;76(suppl IV):IV-68.
  32. Nademanee K, Stevenson WG, Weiss J, Hendrickson JA, Singh BN. Amiodarone prolongs survival in survivors of out-of-hospital cardiac arrest. Circulation 1987;76(suppl IV):IV-175.
  33. Nademanee K, Intarachot V, Robertson HA, Mody FV, Singh BN: Variability of parameters of myocardial ischemia; a comparison of exercise treadmill test,ambulatory ECG monitoring, and symptoms of myocardial ischemia. Circulation, 76(Suppl IV):390, October 1987.
  34. Nademanee K, Gorelick DA, Josephson MA, Robertson HA, Mody FV, Intarachot V. Transient ischemic episodes among cocaine users: evidence of coronary vasospasm. J Am Coll Cardiol 1988;11:204A.
  35. Nademanee K, Christenson PD, Robertson HA, Intarachot V, Harwood BJ, Feild DQ. Role of parasympathetic activity in the diurnal variation of heart rate in man: heart rate spectrum analysis of Holter monitoring. Circulation 1988;78(suppl II).
  36. Nademanee K, Stevenson W, Weiss J, Frame V, Antiamisiaris M, Pruitt C. Frequency-dependent effects of quinidine on ventricular action potential and QRS durations in man. Circulation 1988;78(suppl II):II-4.
  37. Stevenson WG, Weiss J, Wiener I, Nademanee K. Resetting of ventricular tachycardia by stimulation near the suspected reentry circuit: effects of stimulus prematurity. Circulation 1988;78(suppl II):II-4.
  38. Nademanee K, Olukotun Y, Robertson H, Harwood B, Singh BN. Effects of betablockade on the circadian variation of ventricular arrhythmias. J Am Coll Cardiol 1989;13(suppl A) 34A.
  39. Nademanee K, Noll H, Stevenson W, Pruitt C: Autonomic influence on ventricular subsidiary pacemakers: a study of patients post AV nodal ablation. J Am Coll Cardiol 1989;13(suppl A):232A.
  40. Nademanee K, Taylor RD, Noll HE, Robertson HA, Pruitt CM, Rieders DE: Control of electrical storm in patients with recent MI by sympathetic blockade. Circulation 1989;80(4).
  41. Nademanee K, Pacifico A, Antimiasiris M, Taylor A, Taylor R, Boahene A, Chipin L, O’neill P, Pruitt C, Singh B. Electrophysiologic and antiarrhythmic effects of sematilide in humans. Circulation 1990.
  42. Sager P, Nademanee K, Antimisiaris M, Neiditch T, Taylor R, Pruitt C, Singh B. The antiarrhythmic role of selective prolongation of refractoriness: supression of inducible VT with sematilide. J Am Coll Cardiol, 19(2): 309A, March 1992.
  43. Nademanee K, Lu R, Bailey W: A new sensor for tachyrhythmia differentiation– the paced depolarization integral? J Am Coll Cardiol 1992;19:228A.
  44. Hartigan P, Parisi A, Folland E, VA ACME Investigators: angina-free time on treadmill–an alternative method for evaluating anti-anginal therapy in clinical trials: results from the ACME Study. Circulation 1992;19(suppl A):3.
  45. Bailey W M, Nademanee K, Wilkins J, Chipin L, Dungao A. Dose dependent effects of cocaine in catecholamine and sympathetic activities in man. Circulation 1992;86(suppl I);I-582.
  46. Veerakul G, Haveranek E, Henry T, Beavers T, Bailey W, Read R, Harris M, Nademanee K. Intravascular Ultrasound Detections of Aortic Tear from Chest Trauma: Diagnostic Features and Pitfalls. Circulation 1992;6(suppl I);I-845.
  47. Bailey W, Nademanee K, Edwards J, DiPasquale J, Adair O, Friedrich T: Electrophysiologic and hemodynamic effects of dofetilide in patients with severe left ventricular dysfunction. Circulation 1992;86(suppl I): I-205.
  48. Kienzle MG, Buxton AE, Rinkenberger RL, Nademanee K, for the Flecainide SVT Investigators. Circulation 1992;86(suppl I); I-719.
  49. Chun S, Sager P, Stevenson W, Nademanee K, Middlekauff H, Singh B: Amiodarone is highly effective in maintaining nsr in refractory atrial fibrillation/flutter. J Am Coll Cardiol 1992;21:203A.
  50. Bailey W, Nademanee K, Adair O, Britt M, DiPasquale J, Dungao A, Pearson T, Abnormal automatic balance in chronic cocaine use: evidence for persistent excessive sympathetic stimulation. J Am Coll Cardiol 1993;21:285A.
  51. Adair O, Rainguet S, Pearson T, Mallet J, Havranek E, Nademanee K. Echocardiography abnormalities in chronic cocaine users. J Am Coll Cardiol Special Issue 1994;1A-484A:150A94.
  52. Nademanee K, Adair O, Havranek E, Pearson T, Bailey W, DiPasquale J. A prospective study of cocaine related cardiovascular morbidity and mortality: chronic cocaine users vs post-antioplasty patients. J Am Coll Cardiol Special Issue 1994;1A-484A:337A.
  53. Havranek E, Harris M, Nademanee K, Denver General Hospital, University of Colorado Health Sciences Center: Chronic Cocaine Use Impairs Endothelium-Dependent Vasorelaxation. J Am Coll Cardiol Special Issue 1A-484A:274A, February 1994.
  54. Nademanee K, Kosar E, Khong A, Schwab M, McKenzie M, Rieders D, Ransbury T, Drachman D, Wheeler J. School of Medicine, University of Southern California”A New Non-Fluoroscopic Technique of Electro-anatomical Mapping in Radiofrequency Ablation of Atrial Tachyarrhythmias: A Promising Advance” Oral Presentation, NASPE Sessions May 1998, San Diego, CA
  55. Khong A, Nademanee K, Kosar E, Schwab M, McKenzie M, Rieders D, Ransbury T, Drachman D, Wheeler J. School of Medicine, University of Southern California “Does Non-Fluoroscopic 3-D Mapping Aid Arrhythmia Ablation?” Poster Presentation, NASPE Sessions, May 1998, San Diego, CA
  56. Nademanee K, Bailey B, Friedrich T, Satler C, et al. ” Electrophysiologic and Hemodynamic Effects of Dofetilide in Patients with Depressed Left Ventricular Function: A Randomized, Double-Blind, Placebo Controlled Study” Poster Presentation, NASPE Sessions, May 1998, San Diego, CA
  57. Nademanee K, Kosar E, Mehra A, Bhuripanyo K, Rieders D, et al. “Catheter-Based Maze Procedure for Atrial Fibrillation” Poster Presentation at the 71st Annual Scientific Sessions, November 1998, Dallas, Texas
  58. Nademanee K, Kosar E, Bhuripanyo K, Rieders D, et al. “Catheter Ablation for Refractory Multiple Morphologic VT: Values of Non-Fluoroscopic Electroanatomical Mapping” American College of Cardiology 48th Annual Scientific Sessions, March 1999, New Orleans, LA
  59. Wharton J. Marcus, Plumb Vance J., Callans David J., Engelstein Erica D., Constantin L., Lesh Michael, Franklin Jay O., Nademanee Koonlawee, Griffin Joe C. ” Comparison of Acute and Long Term Results of Internal Versus External Atrial Defibrillation.” American Heart Association 72nd Annual Scientific Sessions, Atlanta, GA, November 1999.
  60. Veerakul G., Likittanasombat K, Jirasiriojanakorn K, Chandanamattha P, Nademanee K. Circadian Variation of Spontaneous VF Episodes in Young Thai Men with Normal Hearts. American Heart Association 72nd Annual Scientific Sessions, Atlanta, GA, November 1999.
  61. Krittayaphong R, Veerakul G, Bhuripanyo K, Raungrataamporn O, Nademanee K. Heart Rate Variability in Patients with Sudden Unexpected Death Syndrome in Thailand. North American Society of Pacing and Electrophysiology, Washington, DC, May 2000.
  62. Nademanee K, Kosar E, Vasavakul T, Khunnawat C, Mok D, Schwab M, McKenzie J, Rieders D. Catheter Ablation of Ventricular Tachycardia in Patients with Arrhythmogenic Right Ventricular Dysplasia. North American Society of Pacing and Electrophysiology Scientific Sessions, Washington DC, May 2000.
  63. Nademanee K, Kosar E, Vasavakul T, Khunnawat, C, Witayakul B, Schwab M, Rieders D, and McKenzie J. Catheter Ablation of Atrial Tachycardia in patients with Post-Surgical Correction of Congenital Heart Disease. American Heart Association Scientific Sessions, Anaheim, CA, November 11-14, 2001.
  64. Nademanee K, Veerakul G, Kritayaphong R, Sithisook S, Bhuripanyo K, Littanasombat K, Lai MY, Azen S. Results of a Prospective Randomized Trial Comparing Defibrillators vs. Beta Blockers in Unexplained Death in Thai Men (DEBUT): ICD saves lives. American Heart Association Scientific Sessions, Anaheim, CA, November 11-14, 2001.
  65. Nademanee, M. Pollack S, Miller J. Shrikant G. Electrophysiologic Effects of DTI-0009, A New Novel Adenosine Derivative Compound for Long-Term Therapeutic Use. 23rd Annual Scientific Sessions of the North American Society of Pacing and Electrophysiology (NASPE), San Diego, May 2002.
  66. Nademanee K, Intarachot V, Kosar E, McKenzie J, Ngarmukos J, Karwecki M, Schwab M. Non-Pharmacological Treatment of Atrial Fibrillation: An Idea Whose Time has Come. American Heart Association Scientific Sessions, November 2003.
  67. Daoud E, Hoyt R, Nademanee K, Fuenzalida C, Reeve H, Simones M, Stone C, Schwartz M. Predictors of Implantable Cardioverter Defibrillator Therapy. Poster Presentation. American College of Cardiology Scientific Sessions 2004.
  68. Nademanee K ” Does Maintaining Sinus Rhythm in High Risk Atrial Fibrillation Population Reduce the Risk of Stroke?” The Results of Substrate Ablation and Non-Pharmacological Strategy for Treatment of Atrial Fibrillation (SAN-AFIB) American Heart Association Scientific Sessions 2004, New Orleans, Louisiana.
  69. Suresh B. Neelagaru, Javier E. Sanchez, Stanley K. Lau, Steven M. Greenberg, Nirav Y. Raval, Seth Worley, Jill Kalman, Andrew D. Merliss, Steven Krueger, Mark Wood, Marc Wish, Daniel Burkhoff, Koonlawee Nademanee. Non-Excitatory, Cardiac Contractility Modulation Electrical Impulses: Feasibility Study for Advanced Heart Failure in Patients with Normal QRS Duration. Heart Failure Society 10th Annual Scientific Meeting, Seattle, Washington, September 10-13, 2006.
Back to Top